Chemed Q1 adjusted EPS $5.65; boosts 2026 guidance to $24.00-$24.75 on VITAS momentum

CHEMED CORP

2026-Q1 EPS reported $4.84 revenue$657,513,000

GAAP diluted EPS $4.84, down 0.4% YoY; adjusted EPS $5.65, up 0.4% YoY.
Revenue $657.5M (+1.6%); VITAS revenue $420.0M (+3.1%); Roto-Rooter revenue $237.5M (-0.9%).
VITAS ADC up 2.2% to 22,723; admissions up 6.9%; adjusted EBITDA ex-Medicare Cap $70.8M (+0.6%), margin 16.8%.
Roto-Rooter adjusted EBITDA $53.5M (-9.6%), margin 22.5% (-218bps); acquired two franchises for $20.6M.
FY 2026 adjusted EPS guidance raised to $24.00-$24.75 from $23.25-$24.25; repurchased 500k shares for $197.7M in Q1.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CHEMED CORP reported first quarter ended March 31, 2026 results: revenue $657.5 million, EPS GAAP Diluted Earnings-per-Share (EPS) of $4.84.

Period: first quarter ended March 31, 2026
Revenue: $657.5 million
EPS: GAAP Diluted Earnings-per-Share (EPS) of $4.84
Result: reported results

Exact text from the filing

quarter ended March 31, 2026, versus the comparable prior-year period. Results for Quarter Ended March 31, 2026 Consolidated operating results: · Revenue increased 1.6% to $657.5 million · GAAP Diluted Earnings-per-Share (EPS) of $4.84, a decrease of 0.4% · Adjusted Diluted EPS of $5.65, an increase of 0.4% VITAS segment operating results: · Net Patient Revenue

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

CHEMED CORP filing history →

Source: SEC EDGAR

accession 0000019584-26-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.